Aoyama Renacell Clinic, Begins Joint Research with Juntendo University in the Field of Skin Regeneration Medicine

Strengthening basic research on "W transplant therapy," simultaneous transplantation of dermal fibroblasts and stem cells

2026.05.08 10:00

一般社団法人輝実会青山レナセルクリニック

Aoyama Renacell Clinic (3F, Aoyama NA Building, 2-7-28 Kita-Aoyama, Minato-ku, Tokyo) has recently concluded a joint research agreement with Juntendo University Graduate School of Medicine in the field of skin regenerative medicine.

The joint research aims to scientifically verify and clinically apply the effectiveness of the "W Transplantation Therapy," in which dermal fibroblasts and stem cells are simultaneously transplanted into the skin, which was developed by the hospital in May 2025 as the "ultimate skin regenerative medicine. Professor Hiroshi Mizuno of the Department of Plastic and Reconstructive Surgery will be in charge of this project.

Professor Mizuno is a member of the research team that discovered mesenchymal stem cells in adipose tissue for the first time in the world in 2001, and has served as a visiting professor of plastic surgery at Nippon Medical School, a visiting professor of plastic surgery at the University of California, San Diego, and a council member of the Japanese Society for Regenerative Medicine.

順天堂大学全景

Panoramic view of Juntendo University

As a comprehensive regenerative medicine clinic focusing on stem cell therapy, we have submitted a total of 12 Type 2 Regenerative Medicine Provision Plans to the Ministry of Health, Labour and Welfare for diverse diseases such as diabetes, arteriosclerosis, osteoarthritis, and ED, etc. As for skin regenerative medicine, we provide both stem cell-based therapy and dermal fibroblast transplantation therapy The company provides both stem cell-based therapy and dermal fibroblast transplantation therapy as skin regenerative medicine.

In dermal fibroblast transplantation, a piece of skin is extracted from behind the patient's ear, and the fibroblasts that make up the dermis layer of the skin are extracted, grown, and transplanted to the face and neck.

Unlike fibroblasts, stem cells can remain in the subcutaneous tissue for a long period of time and have a special ability to differentiate into fat cells and other types of cells (pluripotency). This is not possible with fibroblasts.

This stem cell transplantation therapy to the skin is positioned as the best approach for middle-aged and older patients who have deep lines due to atrophy and reduction of fat in the subcutaneous tissue with aging, as well as dark circles under the eyes due to weakening of the dermis layer and deterioration of blood flow, in addition to loss of elasticity and firmness due to the decrease in dermal fibroblasts.

In the process of accumulating clinical experience in transplantation treatment of both stem cells and fibroblasts over the past six years, we have learned that the two types of cells have a high affinity, that fibroblasts have a markedly enhanced collagen-producing capacity when coexisting with stem cells, and that stem cells themselves produce collagen and collagen fibers than fibroblasts.

Therefore, we determined that the simultaneous transplantation of these two types of cells into the skin could maximize the synergistic effect, and since we came up with the idea of "W Transplantation Therapy" in 2025, it has been supported by many patients, both men and women.

Through this joint research with Juntendo University, we aim to improve clinical performance by elucidating the effects of W transplant therapy and accumulating scientific evidence.

W移植治療イメージ